<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00250874</url>
  </required_header>
  <id_info>
    <org_study_id>Myocet 008 (L017)</org_study_id>
    <nct_id>NCT00250874</nct_id>
  </id_info>
  <brief_title>Myocet, Docetaxel &amp; Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer</brief_title>
  <official_title>Phase I-II Study of Liposomal Doxorubicin (Myocet®), Docetaxel and Trastuzumab as First-Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeneus Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeneus Pharma</source>
  <brief_summary>
    <textblock>
      To study the pharmacokinetic profile of the therapeutic schedule in order to demonstrate&#xD;
      absence of negative interactions among the 3 drugs administered&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To assess the maximum tolerated dose (MTD) of Myocet at different dosages in combination&#xD;
           with Taxotere at the fixed dose of 35 mg/m2 on day 2 and 9 every 21 days and weekly&#xD;
           Herceptin as first line therapy in patients affected by HER-2/neu positive metastatic&#xD;
           breast cancer&#xD;
&#xD;
        2. To enhance the proportion of complete remission&#xD;
&#xD;
        3. To allow the feasibility of the combination of Herceptin with both Myocet and Taxotere&#xD;
           without an enhanced risk of cardiotoxicity&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>45</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HER-2/neu overexpression assessed by FISH test or with immunohistochemical methods:&#xD;
             Dako(the result must be 3+ with dakotest); if the immunohistochemical test results 2+&#xD;
             it is needed a positive FISH test&#xD;
&#xD;
          -  Female &lt; 70yrs&#xD;
&#xD;
          -  Histologically or cytologically proven breast cancer.&#xD;
&#xD;
          -  Metastatic or locally advanced breast cancer (clinical stage: III-IV)&#xD;
&#xD;
          -  Adequate hematological, hepatic, renal and cardiac function, the latter confirmed by&#xD;
             echocardiography with FEVS ≥50%&#xD;
&#xD;
          -  Prior adjuvant chemotherapy if doxorubicin total dose ≤300 mg/m2, epirubicin total&#xD;
             dose ≤450 mg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cardiopathy&#xD;
&#xD;
          -  Severe hepatic and renal diseases&#xD;
&#xD;
          -  Brain metastases as the only parameter of disease&#xD;
&#xD;
          -  Contraindication to the use of corticosteroids as premedication&#xD;
&#xD;
          -  Acute infectious diseases&#xD;
&#xD;
          -  Insulin-dependent diabetes&#xD;
&#xD;
          -  History of other cancers except for adequately treated basal cell skin cancer or in&#xD;
             situ carcinoma of the cervix&#xD;
&#xD;
          -  Concurrent treatment with any other cancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Amadori</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Pietrantoni, Forli, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Professor Gasparini</last_name>
    <role>Principal Investigator</role>
    <affiliation>San Filippo Neri, Rome, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Professor Amadori</last_name>
    <phone>+39 0543 731737</phone>
    <email>segronco@ausl.fo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Professor Gasparini</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Pietrantoni</name>
      <address>
        <city>Forli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Professor Amadori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2005</verification_date>
  <study_first_submitted>November 7, 2005</study_first_submitted>
  <study_first_submitted_qc>November 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2005</study_first_posted>
  <last_update_submitted>November 7, 2005</last_update_submitted>
  <last_update_submitted_qc>November 7, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

